A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : HDACs

Search Conditions:
Search Keyword : HDACs
Search Method : Exact match.
Research Area:

Abbreviation: HDACs
Appearance Frequency: 3344 time(s)
Long forms: 19

Display Settings:
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
histone deacetylases
(3272 times)
(487 times)
HATs (338 times)
TSA (204 times)
HDACi (181 times)
1998 Differential expression of human histone deacetylase mRNAs in response to immune cell apoptosis induction by trichostatin A and butyrate.
histone deacetylase enzymes
(18 times)
(3 times)
HDACi (3 times)
ASFV (1 time)
CNN (1 time)
2002 Physical and functional interactions of histone deacetylase 3 with TFII-I family proteins and PIASxbeta.
histone deacetylase complexes
(11 times)
(3 times)
AML (1 time)
APL (1 time)
ATRA (1 time)
2001 The p107 tumor suppressor induces stable E2F DNA binding to repress target promoters.
histone acetyltransferases and deacetylases
(7 times)
Molecular Biology
(2 times)
GC (1 time)
HDAC6 (1 time)
hERG (1 time)
2004 Cytoplasmic sequestration of HDAC7 from mitochondrial and nuclear compartments upon initiation of apoptosis.
Histone deacetylase inhibitors
(6 times)
(2 times)
TSA (2 times)
CAM (1 time)
EGFR (1 time)
2001 Design and synthesis of a novel class of histone deacetylase inhibitors.
histone/protein deacetylases
(6 times)
Allergy and Immunology
(1 time)
Treg (2 times)
CI (1 time)
FOXP3 (1 time)
2009 Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice.
histone deacetyltransferases
(5 times)
(2 times)
Ang II (1 time)
beta-MHC (1 time)
DNMTs (1 time)
2006 Expression of the RERG gene is gender-dependent in hepatocellular carcinoma and regulated by histone deacetyltransferases.
Histone/protein deacetylases
(4 times)
(1 time)
HDACi (3 times)
Treg (2 times)
IRI (1 time)
2007 Deacetylase inhibition promotes the generation and function of regulatory T cells.
histone deacetylase proteins
(3 times)
Molecular Biology
(2 times)
CREB (1 time)
ERbeta (1 time)
iPSCs (1 time)
2012 Regulation of SIK1 abundance and stability is critical for myogenesis.
10  MEF2-histone deacetylases
(3 times)
(1 time)
BDNF (1 time)
CaMKP (1 time)
COPD (1 time)
2009 Current perspectives on role of chromatin modifications and deacetylases in lung inflammation in COPD.
11  heteronuclear dual-atom catalysts
(1 time)
Biomedical Engineering
(1 time)
AC (1 time)
2021 Atomically Dispersed Heteronuclear Dual-Atom Catalysts: A New Rising Star in Atomic Catalysis.
12  histone acetyltransferases, methyltransferases and deacetylases
(1 time)
(1 time)
HMEs (1 time)
2012 Schistosoma mansoni histones: from transcription to chromatin regulation; an in silico analysis.
13  histone deacetylase encoding genes
(1 time)
(1 time)
HDAC (1 time)
HDIs (1 time)
2008 Histone deacetylase (HDAC) encoding gene expression in pancreatic cancer cell lines and cell sensitivity to HDAC inhibitors.
14  histone deacetylase in tumorigenesis
(1 time)
(1 time)
HDACIs (1 time)
LRR (1 time)
SAHA (1 time)
2014 Antitumor action of a novel histone deacetylase inhibitor, YF479, in breast cancer.
15  histone deacetylating enzymes
(1 time)
PTH (1 time)
2016 PTH Signaling and Epigenetic Control of Bone Remodeling.
16  histone lysine deacetylases
(1 time)
Signal Transduction
(1 time)
--- 2014 Histone deacetylases in memory and cognition.
17  histone NAD-dependent deacetylases
(1 time)
Medical Informatics
(1 time)
HDAC (1 time)
SDP (1 time)
SMC (1 time)
2005 Proteins with two SUMO-like domains in chromatin-associated complexes: the RENi (Rad60-Esc2-NIP45) family.
18  hybrid double-atom catalysts
(1 time)
Biomedical Engineering
(1 time)
DACs (1 time)
HER (1 time)
NRR (1 time)
2021 Novel Design Strategy of High Activity Electrocatalysts toward Nitrogen Reduction Reaction via Boron-Transition-Metal Hybrid Double-Atom Catalysts.
19  regulators--histone deacetylases
(1 time)
Drug Therapy
(1 time)
--- 2014 Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.